-
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
NCT07187973 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Greenville
-
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
NCT05431088 ·
Phase: Phase 2, Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Durham, Greenville, Morrisville
-
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
NCT06546670 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years to 55 Years ·
Sex: All (male and female)
· North Carolina: Charlotte, Greenville
-
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226 ·
Phase: Phase 3 ·
Ages: 2 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham, Greenville, Winston-Salem
-
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
NCT06481306 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Greenville
-
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
NCT06612268 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Greenville, Winston-Salem
-
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
NCT06439082 ·
Phase: Phase 3 ·
Ages: 12 Years to 100 Years ·
Sex: All (male and female)
· North Carolina: Greenville, Winston-Salem
-
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
NCT04398628 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Charlotte, Greenville, Winston-Salem
-
ATHNdataset Registry
NCT06820515 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Hickory
-
Achieving Understanding of the Natural History of Sickle Cell Trait (AUNT)
NCT06071377 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Durham, Greenville
-
Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
NCT06941389 ·
Phase: Not specified ·
Ages: 3 Years to 20 Years ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Charlotte
-
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563 ·
Phase: Phase 3 ·
Ages: 12 Years to 35 Years ·
Sex: All (male and female)
· North Carolina: Charlotte
-
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
NCT03587272 ·
Phase: Phase 2 ·
Ages: 2 Years to 25 Years ·
Sex: All (male and female)
· North Carolina: Charlotte
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
NCT06374238 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 16 Years to 30 Years ·
Sex: All (male and female)
· North Carolina: Durham, Greenville
-
Predictors of Pain in Sickle Cell Disease
NCT06139510 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 15 Years to 40 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
NCT04657822 ·
Phase: Phase 4 ·
Ages: 6 Months to 100 Years ·
Sex: All (male and female)
· North Carolina: Greenville
-
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849 ·
Phase: Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· North Carolina: Greenville
-
Sickle Cell Clinical Research and Intervention Program
NCT02098863 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Charlotte
-
SickleFit Exercise and Nutrition Study
NCT07442851 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 35 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
NCT06260891 ·
Phase: Phase 2 ·
Ages: 15 Years to 40 Years ·
Sex: All (male and female)
· North Carolina: Durham